Long-Time Novavax Board Member Jack Marsh Assumes Role of Director Emeritus
June 18 2014 - 04:59PM
GAITHERSBURG, Md.,
June 18, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of recombinant nanoparticle
vaccines and adjuvants, today announced that on June 12, 2014, the
Honorable John O. Marsh, Jr., resigned as a member of its Board of
Directors. Mr. Marsh joined the Board of Novavax in August 1991 and
served as the company's interim CEO and Chairman of the Board from
1996 to 1997. At various times during his 23 years as a Board
member, he has served on all of the Board's various committees.
According to company records kept since 2005, Jack's attendance
rate at Board meetings was in excess of 90%; Mr. Marsh has attended
every board of directors meeting in person or by telephone since
2010. In recognition of his 23 years of service, the Board of
Directors has named Mr. Marsh Director Emeritus.
A lifetime resident of Virginia, Mr. Marsh served in the U.S. Army
during World War II and continued with the Army Reserve and Army
National Guard into the 1960s. A graduate of Washington and Lee
University Law School, Mr. Marsh began practicing law in 1952 in a
variety of state and municipal roles. From 1963 until 1971 he
served as a member of the U.S. House of Representatives. In 1973,
he was appointed Assistant Secretary of Defense, and in January
1974, became the National Security Advisor for then Vice President
Gerald Ford. He subsequently became President Ford's
cabinet-ranking Counsellor to the President. In 1981, Mr. Marsh was
appointed Secretary of the Army by President Ronald Reagan where he
served until 1989. Mr. Marsh has been awarded the Department of
Defense Distinguished Public Service Award on six occasions and was
awarded the Presidential Citizens Medal from President Reagan. Mr.
Marsh has been a Professor of Law and Ethics at various
institutions including the Virginia Military Institute, the College
of William & Mary, and George Mason University. He currently
resides in Winchester, Virginia with his wife.
"Jack's legacy as a board member of Novavax cannot be
underestimated. His leadership at this company paved the way for
our recent years of successful vaccine development," stated Stanley
C. Erck, President and CEO. "Jack's enthusiasm for the company's
business and his continued presence on the Board through some very
difficult early years has allowed Novavax to become a leading
recombinant vaccine development company and to make sustained
progress in our development of important recombinant vaccine
candidates. I am delighted that Jack has agreed to serve as a
director emeritus to the Board where he can continue to mentor and
advise the other members of the Board, as well as our senior
management team."
Chairman of the Board James F. Young, Ph.D. stated, "I am honored
and privileged to have served on the Novavax Board of Directors
with Jack Marsh. Over the last four years, I have learned a great
deal about the company's history and about boardroom
decision-making and diplomacy, witnessing Jack's firm and confident
presence in our boardroom. I am proud to call Jack a friend, and I
look forward to working with him in the future."
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical
company creating vaccines and vaccine adjuvants to address a broad
range of infectious diseases worldwide. Using innovative
proprietary recombinant nanoparticle vaccine technology, the
company produces vaccine candidates to efficiently and effectively
respond to both known and newly emergent diseases.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
|
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novavax, Inc. via Globenewswire
HUG#1795710
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2023 to Mar 2024